New online customer portal for custom research services
Customers to gain a greater insight into their projects, better track project progress and improve communications.
Oxford Genetics has launched a new online customer portal designed to enable customers to better monitor project progress and track communications.
This new portal provides customers with real-time updates through 24/7 access to the status of the projects they have underway with Oxford Genetics. The system collates project information from several sources, including bespoke Enterprise Resource Planning (ERP) systems and Laboratory Information Management (LIM) systems, to produce live Gannt charts.
It also gives immediate access to all supporting documentation, such as order history, quality assurance/quality control (QA/QC) reports, and project progress reports.
Ryan Cawood, CEO of Oxford Genetics said: “The primary reason for developing the tool was that by automating data collection and dissemination many of the traditional bottlenecks of managing projects by manual methods can be eliminated.
"The launch of this portal shows our commitment to providing a more valuable and simplified online environment for our customers. We are focused on delivering both innovative technologies and exceptional service, and the deployment of this online portal helps us enhance the overall experience our customers have with us. By providing customers with visibility of their projects, they can now choose how and when to interact with our team, streamlining their user experience and allowing Oxford Genetics to be more flexible and personally responsive to each customer.
“Added to this, the growth trajectory of Oxford Genetics fed the need to improve efficiencies and streamline operations to allow the company to continue providing a high quality-service to its customers. By implementing this tool across our customer projects, we can use resources more effectively and benefit from a scalable architecture that can support hundreds of concurrent projects.”
The portal has taken around 12 months to build and was extensively tested with key customers to ensure it met the needs of all users.
Adam Marsden, Head of Informatics, Oxford Genetics said: “This new feature puts the power into the hands of our customers. No competitors in our industry have the level of laboratory automation, IT resources and back-end infrastructure to support an online portal like this."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.